Lonza Group AG Stock price

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Delayed Swiss Exchange 11:30:55 2023-09-29 am EDT Intraday chart for Lonza Group AG 5-day change 1st Jan Change
425.60 CHF +0.83% -0.16% -6.07%
Sales 2023 * 6,413 M 7,006 M Sales 2024 * 7,114 M 7,771 M Capitalization 31 614 M 34 535 M
Net income 2023 * 884 M 966 M Net income 2024 * 1,107 M 1,209 M EV / Sales 2023 *
5,16x
Net Debt 2023 * 1,477 M 1,613 M Net Debt 2024 * 2,320 M 2,535 M EV / Sales 2024 *
4,77x
P/E ratio 2023 *
34,7x
P/E ratio 2024 *
27,1x
Employees -
Yield 2023 *
0,85%
Yield 2024 *
0,91%
Free-Float99.70%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.83%
1 week-0.16%
Current month-12.95%
1 month-11.31%
3 months-18.62%
6 months-20.60%
Current year-6.07%
More quotes
1 week
414.90
Extreme 414.9
436.80
1 month
414.90
Extreme 414.9
502.80
Current year
414.90
Extreme 414.9
599.40
1 year
414.90
Extreme 414.9
599.40
3 years
414.90
Extreme 414.9
785.40
5 years
245.10
Extreme 245.1
785.40
10 years
71.75
Extreme 71.75
785.40
More quotes
Date Price Change Volume
23-09-29 425.60 +0.83% 238,940
23-09-28 422.10 -.--% 219,113
23-09-27 422.10 -2.38% 260,396
23-09-26 432.40 +0.07% 210,820
23-09-25 432.10 +1.36% 218,525

Delayed Quote Swiss Exchange, September 29, 2023 at 11:30 am EDT

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (49.9%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (22.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (14.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.5%). Net sales break down geographically as follows: Switzerland (9.7%), Europe (28.3%), the United States (42.3%), Americas (3.8%), Asia (14.2%), Australia and New Zealand (1.3%), Africa (0.3%) and other (0.1%).
Calendar
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
425.60CHF
Average target price
627.41CHF
Spread / Average Target
+47.42%
Consensus
  1. Markets
  2. Equities
  3. Stock Lonza Group AG - Swiss Exchange
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer